Abstract

Recent studies demonstrated reduced blood lysosomal acid lipase (LAL) activity in patients with nonalcoholic fatty liver disease (NAFLD). We aimed to verify hepatic LAL protein content and activity in in vitro and in vivo models of fat overload and in NAFLD patients. LAL protein content and activity were firstly evaluated in Huh7 cells exposed to high-glucose/high-lipid (HGHL) medium and in the liver of C57BL/6 mice fed with high-fat diet (HFD) for 4 and 8 months. LAL protein was also evaluated by immunohistochemistry in liver biopsies from 87 NAFLD patients and 10 controls, and correlated with hepatic histology. Huh7 cells treated with HGHL medium showed a significant reduction of LAL activity, which was consistent with reduced LAL protein levels by western blotting using an antibody towards the N-term of the enzyme. Conversely, antibodies towards the C-term of the enzyme evidenced LAL accumulation, suggesting a post-translational modification that masks the LAL N-term epitope and affects enzymatic activity. Indeed, we found a high rate of ubiquitination and extra-lysosomal localization of LAL protein in cells treated with HGHL medium. Consistent with these findings, inhibition of proteasome triggered dysfunctional LAL accumulation and affected LAL activity. Accumulation of ubiquitinated/dysfunctional LAL was also found in the liver of HFD fed mice. In NAFLD patients, hepatic levels of non-ubiquitinated/functional LAL were lower than in controls and inversely correlated with disease activity and some of the hallmarks of reduced LAL. Fat overload leads to LAL ubiquitination and impairs its function, possibly reducing hepatic fat disposal and promoting NAFLD activity.

Highlights

  • Lysosomal acid lipase (LAL) plays a key role in lipid metabolism by hydrolysing cholesteryl esters and triglycerides in lysosomes [1]

  • Wolman disease (WD) and cholesteryl ester storage disease (CESD) are characterized by massive microvesicular steatosis rapidly evolving to cirrhosis and liver failure [4], with timing and type of clinical phenotype being strongly dependent on the absent (WD), or minimal residual (CESD), enzyme activity

  • Thanks to the availability of a new test on dried blood spot (DBS) [5], which has significantly simplified the determination of LAL activity, LAL function has been evaluated in patients with chronic liver disease, in those with nonalcoholic fatty liver disease (NAFLD) and with cirrhosis due to nonalcoholic steatohepatitis (NASH) [6–10]

Read more

Summary

Introduction

Lysosomal acid lipase (LAL) plays a key role in lipid metabolism by hydrolysing cholesteryl esters and triglycerides in lysosomes [1]. Thanks to the availability of a new test on dried blood spot (DBS) [5], which has significantly simplified the determination of LAL activity, LAL function has been evaluated in patients with chronic liver disease, in those with nonalcoholic fatty liver disease (NAFLD) and with cirrhosis due to nonalcoholic steatohepatitis (NASH) [6–10]. Concerns about the reliability of the DBS test in the context of liver disease have been raised [11], underscoring the need to verify LAL content and activity directly at the target organ, i.e. hepatic, level In this regard, the only data available have been provided very recently by Gomaraschi et al, who found a good correlation between DBS-determined and hepatic LAL activity in NAFLD patients [10]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call